198 related articles for article (PubMed ID: 32719002)
1. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer.
Sasaki A; Kawazoe A; Eto T; Okunaka M; Mishima S; Sawada K; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Akimoto T; Shitara K
ESMO Open; 2020 Jul; 4(Suppl 2):. PubMed ID: 32719002
[TBL] [Abstract][Full Text] [Related]
2. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
[TBL] [Abstract][Full Text] [Related]
3. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
Kawai S; Fukuda N; Yamamoto S; Mitani S; Omae K; Wakatsuki T; Kato K; Kadowaki S; Takahari D; Boku N; Muro K; Machida N
BMC Cancer; 2020 Apr; 20(1):338. PubMed ID: 32316940
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
Kubota Y; Kawazoe A; Sasaki A; Mishima S; Sawada K; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Ishii G; Kuwata T; Shitara K
Clin Cancer Res; 2020 Jul; 26(14):3784-3790. PubMed ID: 32156744
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K
Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
[TBL] [Abstract][Full Text] [Related]
9. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.
Lorenzen S; Thuss-Patience P; Pauligk C; Gökkurt E; Ettrich T; Lordick F; Stahl M; Reichardt P; Sökler M; Pink D; Probst S; Hinke A; Goetze TO; Al-Batran SE
Eur J Cancer; 2022 Apr; 165():48-57. PubMed ID: 35202974
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
16. Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients.
Kim J; Byeon S; Kim H; Yeo JH; Hong JY; Lee J; Lim HY; Kang WK; Kim ST
Target Oncol; 2020 Apr; 15(2):203-209. PubMed ID: 32314267
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma.
Murahashi S; Takahari D; Wakatsuki T; Fukuda N; Ichimura T; Ogura M; Ozaka M; Shinozaki E; Nakayama I; Matsushima T; Osumi H; Chin K; Yamaguchi K
Int J Clin Oncol; 2018 Feb; 23(1):92-97. PubMed ID: 28913565
[TBL] [Abstract][Full Text] [Related]
18. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
Mizukami T; Miyaji T; Narita Y; Matsushima T; Ogura T; Miyagaki H; Kawabata R; Horie Y; Kawaguchi T; Muro K; Hara H; Yamaguchi T; E Nakajima T
Future Oncol; 2021 Jul; 17(19):2431-2438. PubMed ID: 33764163
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y; Yuki S; Sawada K; Nakamura M; Muto O; Sogabe S; Shindo Y; Ishiguro A; Sato A; Tsuji Y; Dazai M; Okuda H; Meguro T; Harada K; Sekiguchi M; Okada K; Ito YM; Sakata Y; Sakamoto N; Komatsu Y
Oncologist; 2022 Aug; 27(8):e642-e649. PubMed ID: 35579511
[TBL] [Abstract][Full Text] [Related]
20. A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
Chen Y; Katayose T; Nagaoka S; Piao Y; Yamaguchi K; Asou H
Gastric Cancer; 2021 Nov; 24(6):1320-1329. PubMed ID: 34050432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
